Cardiometabolic comorbidities and epithelial ovarian cancer risk among African-American women in the African-American Cancer Epidemiology Study (AACES).
Black or African American
/ statistics & numerical data
Aged
Carcinoma, Ovarian Epithelial
/ epidemiology
Case-Control Studies
Diabetes Mellitus
/ epidemiology
Female
Humans
Hyperlipidemias
/ epidemiology
Hypertension
/ epidemiology
Metabolic Diseases
/ epidemiology
Middle Aged
Ovarian Neoplasms
/ epidemiology
Prevalence
United States
/ epidemiology
Cardiovascular disease
Disparities
Ovarian cancer risk
Journal
Gynecologic oncology
ISSN: 1095-6859
Titre abrégé: Gynecol Oncol
Pays: United States
ID NLM: 0365304
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
30
01
2020
accepted:
24
04
2020
pubmed:
5
5
2020
medline:
11
2
2021
entrez:
5
5
2020
Statut:
ppublish
Résumé
Studies that have examined the association between cardiovascular comorbidities and epithelial ovarian cancer (EOC) have yielded inconsistent results. It remains unknown whether cardiometabolic disease is associated with EOC in African American (AA) women, who have a higher prevalence of cardiovascular disease and lower risk of EOC than White women. Here, we estimate the effect of cardiovascular comorbid conditions and EOC risk among AA women. Data were available from 593 ovarian carcinoma patients and 752 controls enrolled in the African American Cancer Epidemiology Study (AACES). Participants were asked to self-report a history of hypertension, hyperlipidemia, and diabetes and any current medication use. The relationship between hypertension, hyperlipidemia, diabetes, and medications taken for these conditions was determined using multivariate logistic regression. Hypertension was associated with an increased risk (adjusted odds ratio (aOR) = 1.32, 95% confidence interval (CI) = 1.01, 1.73), whereas diabetes and hyperlipidemia were associated with a decreased risk (aOR = 0.67, 95% CI = 0.49, 0.91 and aOR = 0.61, 95% CI = 0.47, 0.80, respectively) of EOC. Use of anti-diabetic medication was inversely associated with EOC risk, as was use of lipid lowering medications (in the overall study population), which were predominantly statins. Among women with hypertension, use of anti-hypertensive medications was inversely associated with EOC risk, with associations that were most pronounced for diuretics, ARBs and ACE inhibitors. Hypertension was associated with an increased EOC risk in this patient population, whereas an inverse association was observed for diabetes and hyperlipidemia. The decreased risk of EOC identified with use of anti-hypertensive, anti-diabetes or lipid-lowering medications could have implications for risk reduction strategies.
Sections du résumé
BACKGROUND
Studies that have examined the association between cardiovascular comorbidities and epithelial ovarian cancer (EOC) have yielded inconsistent results. It remains unknown whether cardiometabolic disease is associated with EOC in African American (AA) women, who have a higher prevalence of cardiovascular disease and lower risk of EOC than White women. Here, we estimate the effect of cardiovascular comorbid conditions and EOC risk among AA women.
METHODS
Data were available from 593 ovarian carcinoma patients and 752 controls enrolled in the African American Cancer Epidemiology Study (AACES). Participants were asked to self-report a history of hypertension, hyperlipidemia, and diabetes and any current medication use. The relationship between hypertension, hyperlipidemia, diabetes, and medications taken for these conditions was determined using multivariate logistic regression.
RESULTS
Hypertension was associated with an increased risk (adjusted odds ratio (aOR) = 1.32, 95% confidence interval (CI) = 1.01, 1.73), whereas diabetes and hyperlipidemia were associated with a decreased risk (aOR = 0.67, 95% CI = 0.49, 0.91 and aOR = 0.61, 95% CI = 0.47, 0.80, respectively) of EOC. Use of anti-diabetic medication was inversely associated with EOC risk, as was use of lipid lowering medications (in the overall study population), which were predominantly statins. Among women with hypertension, use of anti-hypertensive medications was inversely associated with EOC risk, with associations that were most pronounced for diuretics, ARBs and ACE inhibitors.
CONCLUSION
Hypertension was associated with an increased EOC risk in this patient population, whereas an inverse association was observed for diabetes and hyperlipidemia. The decreased risk of EOC identified with use of anti-hypertensive, anti-diabetes or lipid-lowering medications could have implications for risk reduction strategies.
Identifiants
pubmed: 32362566
pii: S0090-8258(20)31010-6
doi: 10.1016/j.ygyno.2020.04.700
pmc: PMC8436266
mid: NIHMS1658974
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
123-129Subventions
Organisme : NCI NIH HHS
ID : HHSN261201000028C
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA022453
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK079626
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA142081
Pays : United States
Informations de copyright
Copyright © 2020. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no competing interests.
Références
J Gynecol Oncol. 2015 Jul;26(3):240-1
pubmed: 26197861
Hypertension. 1999 Aug;34(2):320-5
pubmed: 10454461
Ann N Y Acad Sci. 2000 Apr;905:242-59
pubmed: 10818458
J Leukoc Biol. 2009 Sep;86(3):505-12
pubmed: 19477910
Arch Physiol Biochem. 2009 May;115(2):86-96
pubmed: 19485704
Geburtshilfe Frauenheilkd. 2016 Oct;76(10):1050-1056
pubmed: 27761025
Gynecol Oncol. 2019 Nov;155(2):294-300
pubmed: 31495456
Hypertension. 1989 Jun;13(6 Pt 1):589-97
pubmed: 2786847
Medicina (Kaunas). 2016;52(2):89-98
pubmed: 27170481
Int J Cancer. 2019 Mar 1;144(5):991-1000
pubmed: 30006925
Cancer Biol Ther. 2006 Feb;5(2):189-97
pubmed: 16357519
Cancer. 2015 Oct 1;121(19):3444-51
pubmed: 26301456
Oncol Lett. 2018 Jan;15(1):683-690
pubmed: 29422962
Int J Epidemiol. 2011 Dec;40(6):1667-77
pubmed: 21984693
BMC Cancer. 2014 Sep 22;14:688
pubmed: 25242549
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Cancer Causes Control. 2011 Nov;22(11):1545-52
pubmed: 21915616
PLoS One. 2014 Dec 02;9(12):e112257
pubmed: 25464005
JAMA. 2002 Dec 18;288(23):2981-97
pubmed: 12479763
Leukemia. 2002 Apr;16(4):508-19
pubmed: 11960327
Prostate. 2007 Jul 1;67(10):1061-9
pubmed: 17469127
Gynecol Oncol. 2017 Jan;144(1):181-186
pubmed: 27863705
Circulation. 2015 Jan 27;131(4):e29-322
pubmed: 25520374
Am J Public Health. 2016 Sep;106(9):1573-81
pubmed: 27459450
Semin Cancer Biol. 2013 Dec;23(6 Pt B):533-42
pubmed: 24012659
JAMA. 1998 Aug 26;280(8):719-23
pubmed: 9728644
JAMA. 2002 Nov 20;288(19):2421-31
pubmed: 12435255
BJOG. 2018 Jul;125(8):1001-1008
pubmed: 29412502
Int J Gynecol Cancer. 2013 Mar;23(3):402-12
pubmed: 23354371
Int J Cancer. 2016 Jul 15;139(2):291-9
pubmed: 26934358